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G-CSF is a modulator of T-cell and DC functions. Previous reports show that monocytes from
G-CSF-treated (post-G) healthy donors differentiate into tolerogenic DC in vitro in the
presence of autologous serum, containing high levels of IL-10 and IFN-a, and in turn induce
type 1 Treg (Tr1) cells. However, the direct effect of G-CSF on DC differentiation was not
investigated. Here, we show that monocytes differentiated in the presence of exogenous
G-CSF (G-DC) remain CD14
1CD1a
 , but acquire a DC-like morphology, express CD83 and
CD86 and low levels of the tolerogenic markers Ig-like transcript (ILT)4 and HLA-G. G-DC
spontaneously produce IL-10 and, upon stimulation, low levels of IL-12. G-DC display low
stimulatory capacity and induce anergy in naı ¨ve T cells, but do not confer suppressive
function. Therefore, in vitro differentiation of monocyte-derived DC in the presence of G-CSF
can replicate some but not all features of post-G DC. These ﬁndings indicate that the
tolerogenic properties of G-CSF do not exclusively reside in its direct effect on DC, which in
turn induce T-cell anergy, but also in its ability to generate a tolerogenic milieu in vivo,
which is necessary for Tr1 cell induction and cannot be replicated in vitro.
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Introduction
G-CSF was initially identiﬁed as a growth factor for neutrophils
[1]. Inﬂammatory stimuli can induce G-CSF production from
bone marrow stromal cells, endothelial cells, macrophages and
ﬁbroblasts. The G-CSF receptor (G-CSFR, CD114) is expressed on
early myeloid progenitors, mature granulocytes, monocytes/
macrophages [1], endothelial cells and other non-hematopoietic
tissues [2], and also on human T and B cells [3–5]. G-CSF induces
the proliferation of granulocyte progenitors and activates the
effector functions of mature neutrophils [1]; moreover, G-CSF
induces the proliferation and the differentiation of HSC.
Consequently, its current major clinical applications are the
acceleration of neutrophil reconstitution after myelo-suppression
and the mobilization of bone marrow HSC [6]. G-CSF also
induces expansion [7–9] and enhancement of phagocytosis [8] of
the monocyte/macrophage system.
G-CSF modulates T-cell and DC functions [10, 11]. PBMC of
G-CSF-treated healthy volunteers show a reduction of pro-
inﬂammatory cytokines upon LPS stimulation [7, 12–17]. The
proliferation of T cells from G-CSF-treated patients [9] and
healthy stem cell donors [18, 19] is profoundly reduced, due to a
G1 arrest in T-cell cycle [20, 21]. This modulation might
be indirectly mediated by down-regulation of co-stimulatory
Correspondence: Prof. Maria Grazia Roncarolo
e-mail: m.roncarolo@hsr.it
& 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2010. 40: 3097–3106 DOI 10.1002/eji.201040659 Immunomodulation 3097molecules and enhancement of IL-10 production by monocytes
[18, 19, 22, 23]. Moreover, CD4
1 T cells from G-CSF-mobilized
stem cell donors are able to suppress allo-proliferative responses
of autologous T cells in a cell contact-independent manner,
acquiring a type 1 Treg (Tr1)-like cytokine proﬁle [24]. Impor-
tantly, direct exposure of human T cells to G-CSF in vitro does not
induce Tr1 cell differentiation [19, 24, 25]. By contrast,
in vivo administration of G-CSF in mouse models promotes
transplantation tolerance through Tr1 cell induction [26], and
has been proved to be protective in several disease models
[27–30].
DC are highly specialized APC with unique capacity to activate
naı ¨ve and memory T cells. In addition, DC are implicated in the
maintenance of peripheral tolerance. G-CSF preferentially
mobilizes plasmacytoid DC that, in turn, skew T-cell differentia-
tion toward a Th2 phenotype [31]. Moreover, CD14
1 monocytes,
in the presence of autologous serum from G-CSF-mobilized
healthy donors (post-G serum), containing high levels of IL-10
and IFN-a, give rise to tolerogenic Tr1-inducing HLA-DR
1CD86
1
CD80
1CD83
1IL-12
low DC (post-G DC) [32]. Similarly, tolero-
genic APC precursors able to induce IL-10-producing Treg arise in
mice after G-CSF treatment [33]. Altogether, these ﬁndings
indicate that G-CSF in vivo is an inducer of IL-10, which is
implicated in the differentiation and function of tolerogenic DC
[34] and Tr1 cells [35]. However, so far nobody has ever tested
the direct effect of G-CSF during monocyte-derived DC (moDC)
differentiation.
In this report, we show that monocytes differentiated with
G-CSF and IL-4 (G-DC) acquire a DC-like morphology, with up-
regulation of co-stimulatory molecules, spontaneous IL-10
release, and low IL-12 production upon LPS stimulation. G-DC
induce anergic but not suppressive T cells in vitro.
Results
G-CSF drives the differentiation of DC-like cells similar
to post-G DC
G-DC were differentiated from peripheral blood monocytes in the
presence of G-CSF and IL-4 and compared to immature DC (iDC)
differentiated with GM-CSF and IL-4 for 7 days, which in some
cases were exposed to LPS during the last 2 days of culture to
obtain mature DC (mDC). G-DC were differentiated in the
absence of GM-CSF since it masked the effects of G-CSF in terms
of phenotype and cytokine production (data not shown) [36].
The yield of G-DC was 6077.5% less than iDC (n538). A small
portion of G-DC cultures maintained monocyte features, while
most cells became large and granular; neither of the two
populations attached to the plate (data not shown). The most
represented portion of G-DC displayed a DC-like morphology
with eccentric nucleus, large cytoplasm and tiny protrusions, and
was clearly distinct from monocytes, which were smaller and
with the typical bean-shaped nucleus. G-DC were similar to iDC,
although larger, with more granules and dendrites (Fig. 1A).
Moreover, G-DC did not express CD115 and M-DC8 (data not
shown).
G-DC expressed CD14 but not CD1a (Fig. 1B, upper panels),
as already reported for post-G DC [32], HGF-conditioned DC [36]
and DC-10 [37, 38]. Interestingly, some CD14
1 cells also co-
expressed CD16 (Fig. 1B, lower panels). G-DC were HLA-DR
1
CD80
1CD83
1CD86
1 even in the absence of maturation stimuli
(Fig. 1C). G-DC expressed signiﬁcantly higher levels of HLA-DR
(70% versus 22%, p50.0004), CD80 (21% versus 7%,
p50.0257), CD83 (on average 11% versus 4%, p50.0404), and
CD86 (on average 83% versus 21%, po0.0001) compared to iDC
(Fig. 1C). Conversely, compared to mDC, G-DC expressed
signiﬁcantly higher levels of HLA-DR (on average 70% versus
44%, p50.0332) and CD80 (21% versus 6%, p50.0020), but
lower levels of CD83 (on average 11% versus 58%, p50.0040)
and CD86 (on average 83% versus 97%, po0.0001; Fig. 1C).
Interestingly, G-DC did not signiﬁcantly up-regulate co-stimula-
tory molecules and maturation markers upon LPS stimulation
(Supporting Information Fig. 1). Thus, G-DC are phenotipically
similar to post-G and HGF-conditoned DC, which are able to
induce Tr1 cell differentiation [32] and expansion of
FOXP3
1 Treg [36], respectively. Therefore, we investigated the
expression of tolerogenic markers involved in Treg induction on
G-DC. ILT2 was expressed at high levels by G-DC, iDC and mDC
(Fig. 1D). Interestingly, G-DC expressed signiﬁcantly higher
levels of ILT3 (53% versus 16%, p50.0009), ILT4 (26% versus
6%, po0.0001), and HLA-G (46% versus 4%, po 0.0001)
compared to mDC. Moreover, G-DC expressed higher levels of
ILT3 (53% versus 20%, p50.0206), ILT4 (26% versus 11%,
p50.0046) and HLA-G (46% versus 15%, p50.0087)
compared to iDC (Fig. 1D). PD-L1, PD-L2, ICOS-L and CD123
were not up-regulated on G-DC compared to iDC (data not
shown).
G-DC spontaneously produce IL-10 and upon
activation secrete low levels of IL-12
Similar to iDC, G-DC did not produce IL-12 or TNF-a if not
stimulated, and spontaneously produced IL-6 (102782 versus
152777pg/mL). Interestingly, G-DC spontaneously secreted
higher levels of IL-10 compared to iDC (on average 175785
versus 43721pg/mL, p50.0386). Compared to mDC, unstimu-
lated G-DC secreted signiﬁcantly lower levels of IL-6 (102782
versus 8757233 pg/mL, p50.0008), but signiﬁcantly higher
levels of IL-10 (175785 versus 0pg/mL, p50.0002; Fig. 2A).
Upon stimulation, G-DC released similar amounts of
IL-10 (170.2 versus 1.570.4ng/mL), IL-6 (2.570.5 versus
2.770.5ng/mL), and TNF-a (1.770.4 versus 1.470.3ng/mL),
but lower levels of IL-12p70 (0.470.2ng/mL versus 2.770.5
ng/mL, p50.0025), compared to activated iDC. Upon stimula-
tion, mDC did not produce any cytokine, apart from low levels of
IL-6 and IL-10, a feature not due to cell death (as ruled out by
trypan blue exclusion and/or annexin V/propidium iodide
analyses; data not shown), but more likely to cell exhaustion
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low levels of IL-12 upon activation.
G-DC display hypo-stimulatory capacity and promote
T-cell anergy
Priming of naı ¨ve CD4
1 T cells with allogeneic G-DC at 10:1 ratio
resulted in very low T-cell proliferation (on average 85%, range
46–99%, less than the proliferation induced by mDC,
p50.0005). As reference, iDC induced 55% (range 31–89%)
less T-cell proliferation than mDC (p50.0068 between G-DC and
iDC; Fig. 3A, left). Similarly, naı ¨ve CD4
1 T cells primed with
allogeneic G-DC produced 98% less IFN-g (range 83–100%)
compared to T cells primed with mDC (po0.001), while iDC
induced 82% less IFN-g compared to mDC (range 20–93%;
p50.001 between G-DC and iDC; Fig. 3A, right). Thus, G-DC
have lower stimulatory capacity compared to iDC.
Notably, at 1:1 ratio, naı ¨ve T cells primed with allogeneic G-DC
showed a proliferative response, although lower compared to T
cells primed with either iDC or mDC, but signiﬁcantly higher
compared to T cells primed with CD14
1 monocytes (p50.05 for all
statistic analyses shown in Fig. 3B). Thus, G-DC have the functional
properties of DC, since they can prime naı ¨ve T cells.
Naı ¨ve CD4
1 T cells primed with allogeneic G-DC [T(G-DC)],
iDC [T(iDC)], or mDC [T(mDC)] were re-stimulated with mDC
from the same allogeneic donor to assess secondary responses.
G-DC induced anergy in T cells, which proliferated on average
57% (range 37–78%) less than T(mDC) cells (p50.0005). As
reference, T cells stimulated with iDC [T(iDC)] proliferated 36%
less than T(mDC) cells upon re-stimulation (range 0–60%;
p50.0180 between T(iDC) and T(G-DC); Fig. 3C, left). When
Figure 1. G-CSF drives the differentiation of DC-like cells similar to post-G DC. MoDC were differentiated by 7-day culture in the presence of G-CSF
and IL-4 (G-DC), or GM-CSF and IL-4 (iDC), in some cases with the addition of LPS during the last 2 days of culture (mDC). (A) Cytospins were
performed by centrifugation of 10^5 cells onto slides, followed by staining with May Gru ¨nwald-Giemsa (magniﬁcation 60 ). One representative
donor out of four tested in two independent experiments is shown. (B–D) Expression of CD14, CD1a, CD16 (B), HLA-DR, CD80, CD83, CD86 (B and C),
ILT2, ILT3, ILT4 and HLA-G (D) was evaluated by FACS on day 7. A representative donor and the mean1SEM of at least ten donors tested in ﬁve
independent experiments are presented. p o 0.05, p o 0.01, p o 0.001; Mann–Whitney test.
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tion by T(G-DC) cell lines was on average 63% lower (range:
18–98%) compared to that by T(mDC) cell lines (p50.0060). As
reference, T(iDC) cells produced on average 26% less IFN-g
(range 10–75%) compared to T(mDC) cells (p50.0416; Fig. 3C,
right). In conclusion, G-DC display very low T-cell stimulatory
capacity and induce anergy in naı ¨ve T cells. Notably, T(G-DC) cell
anergy was reverted by the addition of IL-2 to the culture (data
not shown).
T cells primed with G-DC acquire a Tr1-like cytokine
proﬁle but do not suppress in vitro
Upon re-stimulation with mDC from the same allogeneic donor
used for their priming, T(G-DC) cells secreted signiﬁcantly higher
levels of IL-10 compared to T(mDC) cells (0.9470.24 versus
0.3670.13ng/mL, p50.035; Fig. 4A). T(G-DC) cell lines
secreted also substantial levels of IFN-g, IL-2, TNF-a and IL-5,
and very low levels of IL-4; however, cytokine levels remained
signiﬁcantly lower compared to those secreted by T(mDC) cell
lines (4.971.1 versus 14.274.3ng/mL of IFN-g, p50.0359;
0.470.2 versus 3.371ng/mL of IL-2, p50.0047; 0.570.1
versus 1.370.4ng/mL of TNF-a, p50.0396; 2.170.7 versus
7.271.5ng/mL of IL-5, p50.0190; 0.03170.006 versus
0.09270.021ng/mL of IL-4, p50.0173). IL-17 was barely
detectable in all conditions tested (data not shown). Upon
polyclonal stimulation, IL-10 release by T(G-DC) cells was
reduced compared to allo-speciﬁc stimulation and reached the
same levels of IL-10 released by polyclonally stimulated T(mDC)
cells (0.5470.17 versus 0.4570.18ng/mL; Supporting Informa-
tion Fig. 2); no statistically signiﬁcant differences were found in
IL-2, IFN-g, TNF-a and IL-5 production between T(G-DC) and
T(mDC) cells. Therefore, T(G-DC) cells display a Tr1-like
cytokine proﬁle upon allo-speciﬁc stimulation.
We next investigated the suppressive ability of T(G-DC) cells.
On average (n55), proliferation of autologous CD4
1 T cells
stimulated with allogeneic mDC (MLC) was not reduced by the
addition of T(G-DC) cells, although the overall proliferation
was substantially lower than that observed in cultures
with mDC (p50.0040; Fig. 4B, left). Only T(G-DC) cells from
one out of ﬁve donors were able to suppress the proliferation of
the MLC (about 72% of suppression; data not shown). On aver-
age (n58), addition of T(G-DC) cells to the MLC increased the
overall levels of IFN-g compared to the MLC alone. However,
levels of IFN-g in T(G-DC)1MLC co-cultures were signiﬁcantly
lower compared to those in T(mDC)1MLC co-cultures
(p50.0079; Fig. 4B, middle). Of notice, in four out of eight
donors tested, individually shown in Fig. 4B, right, addition of
T(G-DC) cells to the MLC suppressed IFN-g release (on average
60% reduction, range 4–100%, of IFN-g production in T(G-DC)1
MLC co-cultures compared to the MLC alone, Fig. 4B, right),
indicating that the tolerogenic potential of G-CSF varies in
different donors, likely because of the genetic background of the
host [39]. Altogether, these results indicate that T(G-DC) cells,
despite their Tr1-like cytokine proﬁle, do not acquire full
suppressive capacity typical of Tr1 cells. The percentage of CD4
1
CD25
1FOXP3
1 T cells was not increased in T(G-DC) cultures
(data not shown), indicating that G-DC did not induce the
expansion of natural Treg.
Addition of IL-10, anti-IL-12 and anti-TNF-a Ab does
not rescue the suppressive ability of T(G-DC) cells
We hypothesized that the insufﬁcient release of IL-10 by G-DC,
coupled with the production of pro-inﬂammatory cytokines,
could contribute to their failure in inducing Tr1 cells. To prove
this hypothesis, we differentiated naı ¨ve T cells with G-DC in the
presence [T(G-DC)1IL-10] or absence [T(G-DC)] of exogenous
IL-10 (10ng/mL) and neutralizing antibodies against IL-12 and
Figure 2. G-DC spontaneously produce IL-10 and upon activation
secrete low levels of IL-12. MoDC were differentiated by 7-day culture
in the presence of G-CSF and IL-4 (G-DC), or GM-CSF and IL-4 (iDC), in
some cases with the addition of LPS during the last 2 days of culture
(mDC). (A and B) DC were washed and seeded in the absence (A) or
presence (B) of LPS and IFN-g; supernatants were collected 48h later to
measure cytokine release. Data show mean1SEM of at least 12
donors tested in six independent experiments. p o 0.05, p o 0.01;
Mann–Whitney test.
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their priming, T(G-DC) cells proliferated 52% less than T(mDC)
cells, while T(G-DC)1IL-10 cells proliferated 62% less than
T(mDC) cells (Fig. 5A, left). No differences were found between
T(G-DC) cells and T(G-DC)1IL-10 cells in terms of IFN-g release
(71% versus 67% less IFN-g than T(mDC) cells, respectively;
Fig. 5A, right).
T(G-DC)1IL-10 cells did not show any suppressive ability on
autologous T cells when added to the MLC (Fig. 5B, left). Similar
data were obtained for IFN-g production (Fig. 5B, right). Of
notice, T(G-DC) cells from one out of the three donors tested
were able to suppress the proliferation of autologous T cells
independently of the presence of exogenous IL-10 and neutra-
lizing antibodies (data not shown), in line with the variability
observed in the previous suppressive assay. Therefore, G-DC were
unable to induce T cells with suppressive capacity even in these
culture conditions.
Discussion
We demonstrate that G-CSF, in combination with IL-4, promotes
the generation of a population of moDC, here called G-DC,
exhibiting a peculiar phenotype. G-DC express CD14 and CD16
but not CD1a, are HLA-DR
1CD80
1CD83
1CD86
1, and express
tolerogenic markers (ILT4 and HLA-G) involved in Tr1 cell
induction [37, 38]. G-DC display hypo-stimulatory capacity and
induce anergic but not suppressive T cells in vitro.
We show that G-CSF not only directly induces moDC differ-
entiation, but also modulates their phenotype and functions
in vitro. Rutella et al. demonstrated that monocytes from G-CSF-
treated healthy donors, exposed to autologous (post-G) serum in
the absence of exogenous cytokines, differentiate into DC-like
cells (post-G DC) with tolerogenic features [32]. G-DC share
some characteristics with post-G DC [32], HGF-conditioned
DC-like cells [36], DC-10 [37, 38] and DC conditioned with
serum from cancer patients [40]. These populations maintain the
expression of CD14 without up-regulating CD1a, express high
levels of HLA-DR and co-stimulatory molecules, produce low
levels of IL-12 upon activation, and are poor stimulators.
G-DC, as well as post-G DC and DC-10, induce a Tr1-like
cytokine proﬁle and anergy in naı ¨ve T cells. However, post-G DC
[32] and DC-10 [37, 38] induce Tr1 cells, whereas G-DC do not
induce suppressive T cells. On the other hand, HGF-conditioned
DC expand FOXP3
1 Treg [36]. The phenotype of post-G DC can
be reproduced by culturing monocytes from G-CSF-treated
healthy donors in the presence of exogenous IL-10 and IFN-a
[32], while DC-10 generation requires IL-10 in combination with
GM-CSF and IL-4; by contrast, G-DC are differentiated in the
absence of IL-10. We can speculate that the presence of
exogenous IL-10 in the culture is essential for the in vitro
generation of tolerogenic DC able to drive Tr1 cell differentiation.
The failure of G-DC to induce suppressive T cells does not depend
on defective IL-10 production, or on the release of IL-12 and TNF-a
by activated G-DC; indeed, the addition of IL-10, together with
blocking antibodies against IL-12 and TNF-a,d u r i n gT - c e l lp r i m i n g
with G-DC does not result in the induction of suppressive Tr1 cells.
Thus, other factors might contribute to the differential tolerogenic
ability of post-G DC and G-DC. ILT2, ILT3 and ILT4 are well-char-
acterized immune inhibitory receptors predominantly expressed on
myeloid and plasmacytoid DC [41]. IL-10 and IFN-a treatment
induces ILT3 and ILT4 expression on moDC, which acquire the
ability to induce Treg [42]; however, another report showed that the
expression of ILT3 on DC is dispensable for the induction of Treg
[43]. ILT3 is up-regulated on post-G DC, but its expression does not
correlate with their ability to inhibit T-cell proliferation (Rutella S.,
personal communication). Accordingly, G-DC are not able to induce
suppressive Tr1 cells despite the expression of ILT3. We recently
demonstrated that the IL-10-driven up-regulation of ILT4 and HLA-G
on DC-10, and HLA-G on T cells, is necessary for Tr1 cell induction
[37, 38]. Notably, ILT4 and HLA-G were expressed at low levels by
G-DC. We can speculate that the low levels of expression of ILT4 and
HLA-G together with low IL-10 production by G-DC contributes to
their inability to induce suppressive Tr1 cells.
Figure 3. G-DC display hypo-stimulatory capacity and promote T-cell
anergy. Naı ¨ve CD4
1 T cells were primed with irradiated (6000rad)
allogeneic G-DC, iDC, or mDC at 10:1 ratio. (A) After 4 days, 50mLo f
supernatant were taken to test IFN-g release (right) and cells were
pulsed for 16h with 1mCi/well
3H-thymidine (left). Data show mean1
SEM of 11 donors for proliferation and 13 donors for IFN-g production,
tested in seven independent experiments. (B) Naı ¨ve CD4
1 T cells were
cultured with irradiated allogeneic DC or CD14
1 monocytes at 1:1 ratio.
After 4 days, cells were pulsed for 16h with 1mCi/well
3H-thymidine.
Data show mean1SEM of three donors. (C) After 14 days of culture,
T cells primed with G-DC [T(G-DC)], iDC [T(iDC)], or mDC [T(mDC)] were
washed and evaluated for their proliferative response to mDC from the
same allogeneic donor. After 2 days, 50mL of supernatant were taken to
test IFN-g release (right) and cells were pulsed for 16h with 1mCi/well
3H-thymidine (left). Data show mean1SEM of 14 donors tested
in eight independent experiments. p o 0.05, p o 0.01, p o 0.001;
Mann–Whitney test.
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G-CSF in vitro does not induce a regulatory phenotype [19, 24,
25]. Conversely, in vivo treatment with G-CSF in mouse models of
stem cell transplantation [26, 29, 44, 45] and autoimmune
diseases [46–48] resulted in induction of peripheral tolerance
through IL-10-producing T cells [10]. Similarly, human T cells
exposed to G-CSF in vivo acquire Tr1-like phenotype and func-
tions [24]. Therefore, indirect mechanisms triggered by G-CSF
are responsible for the induction of peripheral tolerance through
Treg in vivo. Notably, IFN-a and IL-10 are increased in the serum
of G-CSF-treated healthy volunteers [32] and can be implicated
in Tr1 cell induction both directly [49, 50] and indirectly, by
contributing to the differentiation of monocytes into tolerogenic
post-G DC [32]. In addition, the direct effect of G-CSF on DC
could be active also in vivo, particularly at early time points after
G-CSF administration, when the G-CSF serum levels reach the
concentration used in our study [51]. It is also possible that
G-DC, in the presence of persistent high levels of IL-10 in vivo,
further differentiate into DC-10, potent Tr1 cell inducers [37].
Injection of G-CSF in patients affected by Crohn’s disease increases
IL-10-secreting T cells in peripheral blood and enhances accumulation
of plasmacytoid DC in the lamina propria, resulting in clinical beneﬁt
[52]. G-CSF enhances stem cell engraftment after allogeneic HSC
transplantation and prevents prolonged neutropenia, but has a neutral
effect on acute GVH reaction [53] while increasing chronic GVH
reaction, a phenomenon recently associated with increased Th17
differentiation [54]. These apparently contrasting effects could be
ascribed to the fact that G-CSF in vivo acts on different cell types,
which are not yet reconstituted at the time of G-CSF treatment
(lympho-myeloid cells), or which can be dysfunctional (stromal cells)
in allogeneic HSC tranplantation but not in other settings.
In conclusion, we show for the ﬁrst time that G-CSF per se
modulates monocyte differentiation toward tolerogenic DC and
directly modulates DC function. Our ﬁndings broaden the
knowledge of the tolerogenic properties of G-CSF, adding a
potential new mechanism of direct APC modulation, which could
contribute to the induction of Treg in vivo.
Materials and methods
Cell preparation
Human peripheral blood was obtained from healthy donors in
accordance with local committee approval and informed consent
from all participating subjects was obtained. PBMC were separated
by density gradient centrifugation over Lymphoprep (Nycomed
Amersham).
Figure 4. T cells primed with G-DC acquire a Tr1-like cytokine proﬁle but not suppressive capacity. Naı ¨ve CD4
1 T cells were cultured with irradiated
(6000rad) allogeneic G-DC [T(G-DC)] or mDC [T(mDC)] at 10:1 ratio. (A) After 14 days, T-cell lines were washed and re-stimulated with mDC from the
same allogeneic donor. Culture supernatants were collected at 24h (IL-2) and 48h (IL-4, IL-5, IL-10, IL-17, IFN-g and TNF-a), and cytokine levels were
evaluated by Bioplex. Data show mean1SEM of eight donors tested in four independent experiments. (B) After 14 days of culture, T-cell lines were
washed and evaluated for their ability to suppress the proliferation of autologous CD4
1 T cells activated by mDC from the same allogeneic donor (MLC).
After 3 days, 50mL of supernatant were taken to test IFN-g release (middle and right) and cells were pulsed for 16h with 1mCi/well
3H-thymidine (left).
Data show mean1SEM of ﬁve donors for proliferation and eight donors for IFN-g production, tested in three to six independent experiments (left and
middle), and the production of IFN-g by the four suppressive donors (right). p o 0.05, p o 0.01,  p o 0.001; Mann–Whitney test. ND: normal donor.
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CD14
1 monocytes were isolated as the adherent fraction of PBMC
following 1h incubation in RPMI 1640 (Biowhittaker) supplemen-
ted with 10% FBS (Biowhittaker), 100U/mL penicillin/streptomy-
cin (Bristol-Myers Squibb), and 50mM2 - m e r c a p t o e t h a n o l( B i o R a d )
(DC medium) at 371C. Following extensive washing, adherent
monocytes were cultured for 7 days in: 50ng/mL rhG-CSF
(Myelostim, Sanoﬁ-Aventis) and 10ng/mL rhIL-4 (R&D Systems)
(G-DC); 100ng/mL rhGM-CSF (R&D Systems) and 10ng/mL rhIL-4
(iDC); 100ng/mL rhGM-CSF and 10ng/mL rhIL-4, with the
addition of 1mg/mL LPS (Sigma Aldrich) during the last 2 days of
culture (mDC). On day 7, 10
5 differentiated DC were cytospinned 50
at 800rpm. Slides were then stained with May Gru ¨nwald-Giemsa
solutions (100 RT). DC were tested for expression of CD1a, CD14,
HLA-DR, CD11c, CD80, CD83, CD86, CD123, ILT2 (BD Bios-
ciences), ILT3 (Coulter Immunotech), ILT4 (Beckman Coulter) and
HLA-G (Exbion). ICOS-L, PD-L1 and PD-L2 were from eBioscience.
T-cell puriﬁcation and differentiation
CD4
1 T cells were puriﬁed from PBMC by negative selection using
the CD4
1 T-cell Isolation kit (Miltenyi Biotec), according to the
manufacturer’s instructions. A portion of the recovered CD4
1
T cells was cryopreserved for later use, and the remainders were
depleted of CD45RO
1 cells using anti-CD45RO-coupled magnetic
beads and LD negative selection columns (Miltenyi Biotec). In the
puriﬁed cells, the proportion of CD4
1CD45RO
 CD45RA
1 was
consistently greater than 95%. 10
5 DC were cultured with 10
6
allogeneic CD4
1CD45RO
  T cells in 1mL of X-VIVO 15 (Biowhit-
taker), supplemented with 5% pooled AB human serum (Biowhit-
taker), and 100U/mL penicillin/streptomycin (Bristol-Myers
Squibb). After 7 days, rhIL-2 (20U/mL; Chiron) was added, and
cells were expanded for additional 7 days. Fourteen days after
initiation of the culture, T cells were collected, washed and
analyzed for their functions. T cells stimulated with G-DC are
referred to as T(G-DC), with iDC as T(iDC), and with mDC
as T(mDC) cells. Compared to cultures stimulated with mDC,
T(G-DC) cell cultures typically resulted in three- to fourfold
reduction in T-cell expansion. In some experiments, T cells were
cultured with G-DC in the presence or absence of IL-10 (10ng/mL),
and/or 10mg/mL anti-TNF-a and anti-IL-12 blocking antibodies
(R&D systems), and were referred to as T(G-DC)1IL-10 cells.
T-cell proliferation and suppression
To determine DC stimulatory capacity, 5 10^4 naı ¨ve T cells
were stimulated with irradiated (6000 rad) allogeneic DC (10:1,
T:DC; in some cases 1:1) in a ﬁnal volume of 200mL of medium in
96-well round-bottom plates. To analyze the proliferative
capacity of T(G-DC), T(DC-10), or T(mDC) cell lines in response
to the same allo-antigen used for their priming, T cells were
Figure 5. Addition of IL-10, anti-IL-12 and anti-TNF-a antibodies does not rescue the suppressive ability of T(G-DC) cells. Naı ¨ve CD4
1 Tc e l l sw e r e
cultured with allogeneic G-DC at 10:1 ratio, in the absence [T(G-DC)] or presence [T(G-DC)1IL-10] of exogenous IL-10 and blocking antibodies against IL-12
and TNF-a. (A) After 14 days of culture, T-cell lines were washed and evaluated for their proliferative response to mDC from the same allogeneic donor.
After 2 days, 50mL of supernatant were taken to test IFN-g release (right) and cells were pulsed for 16h with 1mCi/well
3H-thymidine (left). Data show
mean1SEM of ﬁve donors for proliferation and seven donors for IFN-g production, tested in three to four independent experiments. (B) After 14 days of
culture, T-cell lineswere washed and evaluated for their ability to suppress the proliferation of autologous CD4
1 T cells activated by mDC from the same
allogeneic donor (MLC). After 3 days, 50mL of supernatant were taken to test IFN-g release (right) and cells were pulsed for 16h with 1mCi/well
3H-thymidine (left). Data show mean1SEM of three donors tested in two independent experiments.
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ﬁnal volume of 200mL of medium in 96-well round-bottom
plates. In some experiments, 100U/mL rhIL-2 were added. To
test the suppressive capacity of T-cell lines, autologous CD4
1
T cells were thawed and 5 10^4 of the cells were stimulated
with irradiated allogeneic mDC (10:1) in the absence or presence
of T(G-DC), T(DC-10) or T(mDC) cells (1:1, T:T) in a ﬁnal
volume of 200mL of medium in 96-well round-bottom plates. All
cultures were performed in triplicate. After the indicated time,
cells were pulsed for 16h with 1mCi/well
3H-thymidine.
Cytokine determination
To measure IL-6, IL-10, IL-12p70 and TNF-a produced by DC,
5 10^4 cells were left unstimulated or activated with 50ng/mL
rhIFN-g (R&D Systems) and 200ng/mL LPS (Sigma) in a ﬁnal
volume of 200mL in 96-well round-bottom plates. Supernatants
were collected after 48h. Levels of IL-6, IL-10, IL-12p70 and
TNF-a were determined by capture ELISA according to the
manufacturer’s instructions (BD Biosciences). The detection
limits were as follows: IFN-g: 60pg/mL; IL-6: 20pg/mL; IL-10:
20pg/mL; IL-12: 20pg/mL; TNF-a: 30pg/mL. To measure IL-2,
IL-4, IL-5, IL-10, IL-17, IFN-g and TNF-a produced by T-cell lines,
5 10^4 cells were stimulated with allogeneic mDC (10:1) or
antiCD3/CD28 mAb, in a ﬁnal volume of 200mL in 96-well
round-bottom plates. Supernatants were harvested after 24h
(IL-2) and 48h (IL-4, IL-5, IL-10, IL-17, IFN-g, and TNF-a).
Cytokine levels were determined by Bioplex according to the
manufacturer’s instructions (Bio-Rad). The detection limits were
as follows: IL-2: 4pg/mL; IL-4: 1pg/mL; IL-5: 6pg/mL; IL-10:
5pg/mL; IFN-g: 5pg/mL; TNF-a: 15pg/mL.
Statistical analysis
All statistical analyses for signiﬁcant differences were performed
with the non-parametric Mann–Whitney test. P-Values r0.05
were considered signiﬁcant.
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